Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

SteamOS is slowly becoming an alternative to Windows for handheld gaming devices. After launching the Steam Deck with SteamOS ...

Upcoming Mahindra XUV 3XO EV spotted in Orissa charging outside Tata dealership without camouflage. Here are the details of ...

The realme C75 has made waves in the tech world, offering features that redefine resilience and endurance in smartphones.

The accelerated approval and rapid distribution of mRNA vaccines introduced a new paradigm in infectious disease response, highlighting the need for swift action. Despite the success of mRNA vaccines, ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is working with genetically… ...

Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.